

## Special Issue

# Resection and Reconstruction for Breast Cancer

### Message from the Guest Editors

Breast cancer is the most common malignancy found in women; according to GLOBOCAN, there were nearly 2.3 million of new cases diagnosed in 2022 and 670,000 deaths, respectively. Therefore, early diagnosis through proper screening, oncologic vigilance and education across the globe and proper combined modality treatment are vital. This also means that breast cancer is a curable disease and there is a vast number of survivors, with many living with various consequences following therapy. Surgery is a cornerstone of combined modality treatment and cannot be omitted in any case. There are two pillars of successful treatment in oncology: survival and the quality of life. Both have been successfully improved by modern surgery of the breast in frames of combined modality treatment. For this special issue of *Cancers*, we welcome manuscripts covering surgical treatment of this very special and numerous group of patients: women touched by breast cancer.

---

### Guest Editors

Dr. Radoslaw Tarkowski

Department of Surgical Oncology, Regional Specialist Hospital, 59220 Legnica, Poland

Dr. Gilles Houvenaeghel

Department of Gynecology, Hôpital Européen, Marseille, France

---

### Deadline for manuscript submissions

30 July 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/250488](https://mdpi.com/si/250488)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)